MarthaGroganMD
Cardiology • Rochester, MNAdult Congenital Heart Disease, Heart Failure & Transplantation
Associate Professor of Medicine, Mayo Medical School
Dr. Grogan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1990 - 1994- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1984
Certifications & Licensure
MN State Medical License 1985 - 2025
OR State Medical License 1994 - 2025
WI State Medical License 1996 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 1997
- Fellow American College of Cardiology, 1994
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Start of enrollment: 2013 Dec 09
Publications & Presentations
PubMed
- Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care.Julian D Gillmore, Katrin Hahn, J Gustav Smith, Isabel Conceição, Zhuang Tian
Cardiology and Therapy. 2025-03-19 - Artificial Intelligence-Enhanced Electrocardiogram: A Possible Mechanism to Monitor Cardiac Amyloidosis Therapeutic Response.Reid P Schlesinger, Iuri Ferreira Felix, David M Harmon, Awais A Malik, Angela Dispenzieri
JACC. Case Reports. 2025-03-19 - 1 citationsEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.Daniel P Judge, Kevin M Alexander, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia
Journal of the American College of Cardiology. 2025-03-18
Journal Articles
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyMathew S Maurer, Mazen Hanna, Martha Grogan, Marla B Sultan, Sanjiv J Shah, The New England Journal of Medicine
Lectures
- Untangling Amyloidosis 201961st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Amyloid Cardiomyopathy: The Starry Future2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Uncommon Cardiomyopathies: Lesser Seen but Still Important2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Join now to see all
Authored Content
- Spectrum of Restrictive and Infiltrative Cardiomyopathies Part 1 of a 2-Part SeriesJanuary 2018
Press Mentions
FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients with ATTR-CMNovember 26th, 2024- BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CMNovember 26th, 2024
- BridgeBio Pharma Receive FDA Nod for AttrubyNovember 25th, 2024
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
